INT101892

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.65
First Reported 2002
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 10
Total Number 30
Disease Relevance 7.19
Pain Relevance 0.85

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (PIM1) plasma membrane (PIM1) nucleus (PIM1)
cell cycle (PIM1) transcription factor binding (PIM1) cytoplasm (PIM1)
PIM1 (Homo sapiens)
Pain Link Frequency Relevance Heat
depression 21 93.20 High High
sSRI 21 91.36 High High
cINOD 105 89.56 High High
beta blocker 84 85.92 High High
opiate 21 85.36 High High
addiction 21 83.00 Quite High
Antihistamine 21 79.92 Quite High
tricyclic antidepressant 84 77.28 Quite High
Central nervous system 47 63.60 Quite High
Chronic pancreatitis 3 50.00 Quite Low
Disease Link Frequency Relevance Heat
Cancer 205 100.00 Very High Very High Very High
Mantle-cell Lymphoma 165 99.60 Very High Very High Very High
Emergencies 42 96.14 Very High Very High Very High
Incontinence 21 95.64 Very High Very High Very High
Cognitive Disorder 21 94.92 High High
Disease 314 94.04 High High
Depression 21 93.20 High High
Syncope 21 89.92 High High
Delirium 21 89.50 High High
Increased Venous Pressure Under Development 21 89.44 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The prevalence of PiM variants was higher in patients with early onset CP than in late onset (P < 0.05 for E376D).
Gene_expression (prevalence) of PiM
1) Confidence 0.65 Published 2002 Journal Scand. J. Gastroenterol. Section Body Doc Link 11916201 Disease Relevance 0.07 Pain Relevance 0
There was a statistically significant correlation between the PIM score and cTnT (r = 0.41, p = 0.004).
Gene_expression (score) of PIM
2) Confidence 0.25 Published 2006 Journal Crit Care Section Body Doc Link PMC1751080 Disease Relevance 0.38 Pain Relevance 0
There was no correlation between the PIM score and the cTnT levels in the neonates (r = 0.27, p = 0.22).
Gene_expression (score) of PIM
3) Confidence 0.25 Published 2006 Journal Crit Care Section Body Doc Link PMC1751080 Disease Relevance 0.05 Pain Relevance 0
In the 25 older paediatric intensive care admissions, the correlation between the PIM score and cTnT remained significant (r = 0.44, p = 0.028).
Gene_expression (score) of PIM
4) Confidence 0.25 Published 2006 Journal Crit Care Section Body Doc Link PMC1751080 Disease Relevance 0 Pain Relevance 0
Immunohistochemical analysis of a cohort of 33 human MCL show that elevated expression of Pim-1 occurs in 42% of cases with elevated Pim-2 occurring in 9% of cases, all of which also express Pim-1.
Gene_expression (expression) of Pim associated with mantle-cell lymphoma
5) Confidence 0.17 Published 2008 Journal J Hematop Section Body Doc Link PMC2713479 Disease Relevance 0.62 Pain Relevance 0
Immunohistochemical analysis of a cohort of 33 human MCL show that elevated expression of Pim-1 occurs in 42% of cases with elevated Pim-2 occurring in 9% of cases, all of which also express Pim-1.
Gene_expression (express) of Pim associated with mantle-cell lymphoma
6) Confidence 0.17 Published 2008 Journal J Hematop Section Body Doc Link PMC2713479 Disease Relevance 0.67 Pain Relevance 0
High levels of Pim expression, as occurs in tumors, active, but not inactive, Pim-1 or Pim-2 blocks the degradation of both p53 and Mdm2 in a manner that is independent of Mdm2 phosphorylation, leading to increased p53 levels and, proportionately, p53-dependent transactivation.
Gene_expression (expression) of Pim associated with cancer
7) Confidence 0.17 Published 2008 Journal J Hematop Section Body Doc Link PMC2713479 Disease Relevance 0.86 Pain Relevance 0
These data are consistent with the idea that Pim normally interacts with the p53 pathway but, when expressed at pathological levels, like in MCL, behaves as a classic dominant oncogene that stimulates a protective response through the induction of the p53 pathway [11].
Gene_expression (expressed) of Pim associated with mantle-cell lymphoma
8) Confidence 0.14 Published 2008 Journal J Hematop Section Body Doc Link PMC2713479 Disease Relevance 0.67 Pain Relevance 0
High levels of Pim expression, as occurs in tumors, active, but not inactive, Pim-1 or Pim-2 blocks the degradation of both p53 and Mdm2 in a manner that is independent of Mdm2 phosphorylation, leading to increased p53 levels and, proportionately, p53-dependent transactivation.
Gene_expression (expression) of Pim associated with cancer
9) Confidence 0.14 Published 2008 Journal J Hematop Section Body Doc Link PMC2713479 Disease Relevance 0.92 Pain Relevance 0
The performance of the STOPP and Beers criteria has been evaluated for detecting PIM prescribing and related ADRs in 715 older patients admitted a university teaching hospital in Ireland.44 The STOPP identified 336 PIMs affecting 35% of patients, one-third of whom presented with an associated ADE, while the Beers’ criteria identified 226 PIMs affecting 25% of patients, of whom 43% presented with an associated ADE.
Gene_expression (detecting) of PIM
10) Confidence 0.05 Published 2010 Journal Clin Interv Aging Section Body Doc Link PMC2854054 Disease Relevance 0.15 Pain Relevance 0.16
In order to address this public health concern in older adults, particularly within the hospital environment, it is crucial that clinicians have an understanding of potential risk factors for PIM prescribing, advantages and limitations of validated drug evaluation tools for identifying PIM prescribing, and possible strategic approaches to curtailing the problem.
Gene_expression (prescribing) of PIM
11) Confidence 0.05 Published 2010 Journal Clin Interv Aging Section Body Doc Link PMC2854054 Disease Relevance 0.07 Pain Relevance 0
The authors concluded that compared to the Beers’ criteria the STOPP criteria are more sensitive in identifying patients liable to suffer harm from an ADE because of PIM prescribing.
Gene_expression (prescribing) of PIM
12) Confidence 0.05 Published 2010 Journal Clin Interv Aging Section Body Doc Link PMC2854054 Disease Relevance 0.22 Pain Relevance 0.38
Presently, four tools exist to evaluate PIM prescribing in older adults.5 The Beers’ Criteria, Improved Prescribing in the Elderly Tool (IPET), and Screening Tool of Older Persons (STOPP) are explicit approaches, while the Medication Appropriateness Index (MAI) is an implicit model.
Gene_expression (prescribing) of PIM
13) Confidence 0.05 Published 2010 Journal Clin Interv Aging Section Body Doc Link PMC2854054 Disease Relevance 0.15 Pain Relevance 0
In order to address this public health concern in older adults, particularly within the hospital environment, it is crucial that clinicians have an understanding of potential risk factors for PIM prescribing, advantages and limitations of validated drug evaluation tools for identifying PIM prescribing, and possible strategic approaches to curtailing the problem.
Gene_expression (prescribing) of PIM
14) Confidence 0.05 Published 2010 Journal Clin Interv Aging Section Body Doc Link PMC2854054 Disease Relevance 0.12 Pain Relevance 0
Conceptually, PIM prescribing in the inpatient setting is a multi-faceted function of the patient, prescriber, and environment.
Gene_expression (prescribing) of PIM
15) Confidence 0.05 Published 2010 Journal Clin Interv Aging Section Body Doc Link PMC2854054 Disease Relevance 0.06 Pain Relevance 0
Factors that contribute to PIM prescribing include inadequate training in geriatric pharmacotherapy as well as the absence of communication between providers practicing in different settings, or between specialists and the primary care provider.
Gene_expression (prescribing) of PIM
16) Confidence 0.05 Published 2010 Journal Clin Interv Aging Section Body Doc Link PMC2854054 Disease Relevance 0 Pain Relevance 0
While tools are available to identify PIM prescribing and potential strategies exist to curtail the problem, several fundamental issues still exist.
Gene_expression (prescribing) of PIM
17) Confidence 0.05 Published 2010 Journal Clin Interv Aging Section Body Doc Link PMC2854054 Disease Relevance 0.08 Pain Relevance 0
A number of studies have documented that potentially inappropriate medication (PIM) prescribing in older adults is common in the ambulatory setting, nursing homes, and the emergency department and that exposure to inappropriate medications is associated with increased morbidity, mortality, health care resource utilization, and ADEs.5 However, limited data exist regarding PIM prescribing in the acute care setting, although adults aged 65 years or older account for over 35% of annual hospital admissions.6–10 Older adults are also at increased risk for hospital readmission.
Gene_expression (prescribing) of PIM associated with emergencies
18) Confidence 0.05 Published 2010 Journal Clin Interv Aging Section Body Doc Link PMC2854054 Disease Relevance 0.15 Pain Relevance 0.04
In the US, the Beers’ criteria have become the most popular and accepted explicit tool used for evaluating PIM prescribing.
Gene_expression (prescribing) of PIM
19) Confidence 0.05 Published 2010 Journal Clin Interv Aging Section Body Doc Link PMC2854054 Disease Relevance 0.79 Pain Relevance 0.09
Hospitalization has been associated with a higher incidence of adverse outcomes including functional decline, delirium, and falls as well as ADEs in this population.12,13 A meta-analysis of 39 studies found an inhospital incidence of ADEs of 6.7% and an incidence of fatal ADEs of 0.3%, which may be slightly higher than what has been documented in the outpatient setting.14,15 Furthermore, older adults in the inpatient setting may be exposed to new and possibly unnecessary medications, multiple providers and specialists, and restrictive hospital formularies that require reconciliation with home medications; all of these can increase the risk for PIM prescribing.16,17
Gene_expression (risk) of PIM associated with delirium
20) Confidence 0.05 Published 2010 Journal Clin Interv Aging Section Body Doc Link PMC2854054 Disease Relevance 0.09 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox